San Diego-based mostly Viking Therapeutics marked itself as a significant competitor while in the weight loss drug industry in February after revealing promising knowledge from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March the co